[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@ShortShitStocks Avatar @ShortShitStocks AustinB

AustinB posts on X about accounting, earning, $dcth, $320m the most. They currently have XXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: XXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence finance

Social topic influence accounting, earning, $dcth, $320m, $100m, profitable

Top assets mentioned Hundred Million (100M)

Top Social Posts #

Top posts by engagements in the last XX hours

"@TOWiU2 FYI my career is in what I can best summarize as atypical-biotech-CMC. Not that you have any reason to trust me but Im not clueless on this topic"
X Link @ShortShitStocks 2025-09-30T15:26Z XXX followers, XX engagements

"@SamuBaaa Thanks. For some reason I thought that was due to a one-off accounting situation but my memory may be off. Either way the point is the company will be earning a lot more in the near future"
X Link @ShortShitStocks 2025-10-18T12:44Z XXX followers, XXX engagements

"$DCTH +25% is not enough. These results are strongly compelling for a new SOC - and as indications expand I expect that to eventually cover the majority of all liver metastases. At Friday close the EV of the company was $320M. -Current annual revenues (4x last Q) $100M -Turning profitable in 2026 -Y/Y revenues doubling -Onboarding new commercial sites at a rapid pace -High barrier to entry even after patent expiry supporting higher valuation multiplier -Clinical trials ongoing to expand to much larger indications *All this before the new compelling clinical data now pushing Hepzato as a new"
X Link @ShortShitStocks 2025-10-18T11:06Z XXX followers, 5863 engagements